You are here

Novel Reagent-less Protein Detection Using Nanotechnology

Award Information
Agency: National Aeronautics and Space Administration
Branch: N/A
Contract: NAS9-02084
Agency Tracking Number: 012614
Amount: $70,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2002
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
7610 Eastmark Drive
College Station, TX 77840
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Waheguru Singh
 Principal Investigator
 (979) 693-0017
 waheguru.singh@lynntech.com
Business Contact
 Dunca Hitchens
Title: Vice President
Phone: (979) 693-0017
Email: duncan.hitchens@lynntech.com
Research Institution
N/A
Abstract

Health care and medical intervention during missions, particularly those of extended duration, can be improved using medical instruments, which allow in flight specimen analysis of blood proteins. Current technologies based upon ELISAs can not meet NASA needs as it only quantitate a single protein at a time. Due to the complicated procedure for antibody immobilization, limited stability, and poor compatibility for biological materials have strongly diminished the apparent attraction of immuno-sensors. Other newly emerging techniques in the field of proteiomics depend upon mass spectrometry methods thus require extensive laboratory support and equipment. These limitations could be overcome by using artificial receptors, which mimic the active sites of antibodies. During the Phase I, Lynntech has prepared sensor elements capable of recognizing different proteins selectively from complex biological samples. Results obtained in Phase I have demonstrated the feasibility of miniatuarization of this technology with minimal power requirements. The proposed research will result in a light weight, hand held device capable of specific recognition of small concentrations of target proteins from biological fluids at the end of Phase II and will be delivered to NASA/JSC. The rapid and simultaneous quantitation of a large number of proteins in biological fluids will become a valuable tool in clinical diagnostics.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government